French-Bel­gian biotech banks €20M to break ground in blood-splat­tered field of ther­a­peu­tic can­cer vac­cines

About a decade ago, the ill-fat­ed ther­a­peu­tic can­cer vac­cine — Provenge — was ap­proved, even­tu­al­ly bank­rupt­ing its de­vel­op­er Den­dreon. Since then, a num­ber of drug­mak­ers have seen sim­i­lar ef­forts splut­ter and fiz­zle, al­though the emer­gence of im­munother­a­pies — check­point in­hibitors and CAR-T drugs — of­fered a glim­mer of hope in re­sus­ci­tat­ing the field. Bank­ing on that promise is PDC*line Phar­ma, which se­cured a €20 mil­lion in­jec­tion on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER